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Introduction: Although attenuated psychotic symptoms often occur for the first time
during adolescence, studies focusing on adolescents are scarce. Attenuated psychotic
symptoms form the criteria to identify individuals at increased clinical risk of developing
psychosis. The study of individuals with these symptoms has led to the release of
the DSM-5 diagnosis of Attenuated Psychosis Syndrome (APS) as a condition for
further research. We aimed to characterize and compare hospitalized adolescents with
DSM-5-APS diagnosis vs. hospitalized adolescents without a DSM-5-APS diagnosis.
Methods: Interviewing help-seeking, hospitalized adolescents (aged 12–18 years) and
their caregivers independently with established research instruments, we (1) evaluated
the presence of APS among non-psychotic adolescents, (2) characterized and compared
APS and non-APS individuals regarding sociodemographic, illness and intervention
characteristics, (3) correlated psychopathology with levels of functioning and severity of
illness and (4) investigated the influence of individual clinical, functional and comorbidity
variables on the likelihood of participants to be diagnosed with APS.
Results: Among 248 consecutively recruited adolescents (age=15.4 ± 1.5 years,
females = 69.6%) with non-psychotic psychiatric disorders, 65 (26.2%) fulfilled APS
criteria and 183 (73.8%) did not fulfill them. Adolescents with APS had higher number
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of psychiatric disorders than non-APS adolescents (3.5 vs. 2.4, p < 0.001; Cohen’s
d = 0.77), particularly, disruptive behavior disorders (Cramer’s V = 0.16), personality
disorder traits (Cramer’s V = 0.26), anxiety disorders (Cramer’s V = 0.15), and eating
disorders (Cramer’s V = 0.16). Adolescents with APS scored higher on positive (Cohen’s
d = 1.5), negative (Cohen’s d = 0.55), disorganized (Cohen’s d = 0.51), and general
symptoms (Cohen’s d = 0.84), and were more severely ill (Cohen’s d = 1.0) and
functionally impaired (Cohen’s d= 0.31). Negative symptoms were associated with lower
functional levels (Pearson ρ = −0.17 to −0.20; p = 0.014 to 0.031). Global illness
severity was associated with higher positive, negative, and general symptoms (Pearson
ρ = 0.22 to 0.46; p = 0.04 to p < 0.001). APS status was independently associated
with perceptual abnormalities (OR = 2.0; 95% CI = 1.6–2.5, p < 0.001), number of
psychiatric diagnoses (OR = 1.5; 95% CI = 1.2–2.0, p = 0.002), and impaired stress
tolerance (OR = 1.4; 95% CI = 1.1–1.7, p = 0.002) (r2 = 0.315, p < 0.001).
Conclusions: A considerable number of adolescents hospitalized with non-psychotic
psychiatric disorders meet DSM-5-APS criteria. These help-seeking adolescents have
more comorbid disorders and more severe symptoms, functional impairment, and
severity of illness than non-APS adolescents. Thus, they warrant high intensity
clinical care.
Keywords: Attenuated Psychosis Syndrome (APS), adolescence, epidemiology, risk, psychosis, prevention
INTRODUCTION
Psychotic disorders, such as schizophrenia, are usually preceded
by a clinical high-risk for psychosis (CHR-P) state (1), which
is characterized by subtle symptoms, functional impairment
and help-seeking behavior (2–4), as well as non-psychotic
comorbidity (5, 6). The CHR-P state, which includes individuals
at ultra-high risk for psychosis and/or those with basic
symptoms, has allowed preventive efforts to be implemented
(7, 8). This area of clinical research has grown until it has
become one of the most established preventive approaches in
psychiatry (7, 8).
The achievements and challenges of the CHR-P paradigm
have been recently appraised by an umbrella review (9). In
brief, three CHR-P subgroups have been established: attenuated
psychotic symptoms; brief limited and intermittent psychotic
symptoms (BLIPS) and genetic risk and deterioration (GRD)
syndrome (9, 10). There are substantial diagnostic (11),
prognostic (10, 12), clinical (13), and therapeutic (14) differences
across these three subgroups. For example, psychosis risk is
higher in the BLIPS group (38%) than in the attenuated psychotic
symptoms group (24%) and higher in both groups than in the
GRD group (8%) at >48 months follow-up (10).
Althoughmost research and clinical studies have evaluated the
three groups together (15–17), the most common group by far is
the attenuated psychotic symptoms group, which includes 85%
of CHR-P individuals (10). Psychosis-risk syndromes, including
attenuated psychotic symptoms, are usually characterized using
semi-structured interviews as the Structured Interview for
Psychosis-Risk Syndromes (SIPS) (18, 19) or the Comprehensive
Assessment of At-Risk Mental States (CAARMS) (1), which
have comparable prognostic accuracy (20). In the SIPS,
the characterization used is Attenuated Positive Symptoms
Syndrome (APSS). Seven years ago, the DSM-5 introduced
the Attenuated Psychosis Syndrome (APS) diagnosis in the
research appendix, listed in both section II and section III
(21) (Figure 1). This diagnosis is defined by the presence of
delusions, hallucinations, or disorganized speech in attenuated
form, but with sufficient severity and frequency to warrant
clinical attention (23, 24) (Figure 1). The diagnostic, prognostic,
and therapeutic characteristics of this diagnosis have been
recently appraised by a systematic review and meta-analysis (21).
This review concluded that DSM-5-APS criteria have received
substantial concurrent and prognostic validation, mostly driven
by research in adult populations (21). A previous study looking
at the agreement between CAARMS and DSM-5-APS criteria
found that the agreement was only moderate (kappa 0.59) (25).
Meanwhile, as findings from other studies point out (26, 27), SIPS
and DSM criteria for APS are more similar (Figure 1).
While most reports to date on APS are based on cohorts that
also include adults (25, 28–30), APS features often occur for
the first time in adolescence (31, 32). Broadly speaking, studies
that focus on DSM-5-APS in adolescents are scarce (21, 22), and
there are few studies on APS in adolescents in clinical care and
hospital settings.
To our knowledge, only a few efforts have been made (22, 33,
34) to characterize APS, excluding other ultra-high risk criteria,
and advance knowledge specifically in children and adolescents,
comparing them to other help-seeking individuals. Among them,
22 APS individuals were compared to other treatment-seeking
individuals and healthy controls regarding clinical and cognitive
features (34), finding that APS was associated with impaired
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FIGURE 1 | DSM-5-APS Attenuated Psychosis Syndrome diagnostic criteria compared with SIPS operationalization [adapted from (Gerstenberg et al. (22); Salazar De
Pablo et al. (21)]. APS, Attenuated Psychosis Syndrome; APSS, Attenuated Positive Symptoms Syndrome; SIPS, Structured Interview for Psychosis-Risk Syndromes.
neurocognition. Also, APS was associated with self-reported
internalizing problems and thought problems in a study with 7
APS adolescents (33). One further study without a comparison
group found that an older age of APS presentation in adolescents
(comparing 9–14 years vs. 15–18 years) was associated with better
social and role functioning and fewer depressive symptoms (35).
There is little evidence on howmany help-seeking adolescents
accessing inpatient care meet APS criteria. Our preliminary
data from the Adolescent Mood Disorder and Psychosis Study
(AMDPS) clinical study compared the first 21 APS and 68
non-APS adolescents who were recruited and found that APS
was present in 23.6% of psychiatrically hospitalized adolescents,
who suffered from a broad range of psychiatric symptoms and
disorders (22).
Although specific knowledge for APS is limited, CHR-P
individuals show impairments in work, educational and social
functioning as well as poor quality of life (9, 36). Furthermore,
psychopathology can adversely influence functioning (37).
Negative symptoms have been associated with functioning, both
daily (38), work related (39) and real-world functioning (40).
Among CHR-P individuals, the severity of attenuated positive
and negative symptoms has been associated with some outcomes
[e.g., transition to psychosis (9, 21)] but not with others [e.g.,
cannabis use (9)]. Our preliminary results showed that poorer
functioning in adolescents with APS was associated with more
severe attenuated positive, negative, and general symptoms (22).
In the CHR-P field, the influence of sociodemographic and
clinical variables on diagnostic and treatment outcomes has
been widely studied, particularly regarding the transition to
psychosis (41–45). Unusual thought content and suspiciousness
have been found to predict conversion to psychosis along
with decline in social functioning, lower verbal learning and
memory performance (46). However, there is no convincing
evidence of the association between any variable and the onset
of psychotic disorders according to a meta-analysis, and only
attenuated positive psychotic symptoms and global functioning
show suggestive evidence (47). The influence of demographic
and clinical variables on the presence of APS, particularly in
adolescents, is even less known. In the first 89 individuals
recruited into AMDPS, lowest GAF score in the past year, and
social isolation were independently associated with APS (22).
The current study analyzes the final sample of this cohort
of hospitalized adolescents to (1) assess how many non-
psychotic, help-seeking adolescents accessing inpatient care meet
APS criteria, (2) describe and compare both groups regarding
sociodemographic, illness and intervention characteristics, (3)
correlate attenuated positive, negative, general and disorganized
symptoms with the level of functioning and severity of illness,
and (4) investigate the influence of individual clinical, functional
and comorbidity variables, selected empirically, on the likelihood
of participants to be diagnosed with APS.
Based on prior literature, we hypothesized that (1) a
significant number of adolescents with non-psychotic psychiatric
disorders would fulfill APS criteria, (2) APS individuals would
report significant comorbidity, clinical burden and functional
impairment that would exceed those of non-APS individuals, (3)
severity of negative symptoms would be significantly associated
with the level of functioning and severity of illness, and (4)
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APS status would be associated with specific attenuated positive
symptoms and other clinical variables.
MATERIALS AND METHODS
Design and Setting
AMDPS was registered at ClinicalTrials.gov (NCT01383915).
Participants were recruited consecutively into AMDPS
between September 2009 and July 2017 from the Adolescent
Child and Adolescent Inpatient Unit of The Zucker Hillside
Hospital, New York, USA (48, 49). AMDPS is an ongoing,
prospective study that aims to assess predictors of the
development of bipolar disorder and psychotic disorders in
hospitalized adolescents. Analyses for this study are restricted
to baseline data. The protocol was approved by the Institutional
Review Board of the North Shore-Long Island Jewish Health
System in accordance with the Helsinki Declaration of 1975
and the UNESCO Universal Declaration on human rights.
Written informed consent was obtained from subjects aged 18 or
the guardians/legal representatives of minors, obtaining written
assent from the minors.
Participants
Inclusion criteria for AMDPS study were: (1) age 12–18 years;
(2) hospitalized at the adolescent inpatient unit of The Zucker
Hillside Hospital, a self-standing psychiatric hospital; (3)
admission chart diagnosis of any bipolar-spectrum disorder,
cyclothymia, major depressive disorder, depressive disorder
not otherwise specified (NOS), dysthymia or mood disorder
NOS, schizophrenia, schizoaffective disorder, schizophreniform
disorder or psychotic disorder NOS, re-evaluated by research
interview, using the Structured Clinical Interview for DSM
Disorders (SCID) (50), supplemented for missing pediatric
diagnoses by the Schedule for Affective Disorders and
Schizophrenia for School-Age Children-Present and Lifetime
version (K-SADS-PL) (51); (4) subject and guardian/caregiver
(if subject<18) willing and able to provide written, informed
consent/assent. Exclusion criteria were: (1) an estimated
premorbid IQ<70; (2) DSM-5 clinical criteria for autism
spectrum disorders or pervasive developmental disorder and (3)
history of any neurological or medical condition known to affect
the brain.
For the purpose of this study, we also excluded patients: (1)
with a psychotic disorder according to DSM-5 criteria; (2) in
whom the Structured Interview for Psychosis-Risk Syndromes,
version 4.0 (52) was not completed (Figure 2).
Psychiatric diagnoses were established in diagnostic research
consensus conferences based on in-person independent
interview assessments of the adolescents and caregivers
whenever possible. The interviews were typically conducted a
few days after hospital admission. In consensus conferences,
both assessments were integrated assuming that symptoms are
more likely forgotten or hidden than invented or exaggerated.
Also, SIPS items were discussed one by one for both interviews
to reach to the correct value, and every psychiatric primary or
comorbid diagnosis, including APS, was discussed among all
the attendees and confirmed by the study lead (CUC). In order
to conduct AMDPS assessments, experienced clinicians had to
be certified by the study PI (CUC) after having gone through a
structured training program, which involved observing several
assessments, followed by conducting several assessments in front
of one of the certified trainers, and presenting their ratings as
part of a diagnostic consensus conference led by the study PI.
All raters continually took part in the diagnostic consensus
conference, during which all interview ratings were discussed
and finalized as part of a group consensus, which served to
assure validity of the ratings, facilitate interrater reliability via
consensual rating, and avoid rater drift after completion of the
initial training and certification.
Diagnostic Assessments
The Structured Interview for Psychosis-Risk Syndromes (SIPS)
(18, 19) is a semi-structured interview used to diagnose
psychosis-risk syndromes in the last month. We used SIPS
Version 4.0 (53). It includes four primary sections according to
the symptoms evaluated: attenuated positive symptoms, negative
symptoms, disorganized symptoms, and general symptoms. As
part of the SIPS, the Scale of Prodromal Symptoms (SOPS) is
used to determine whether participants meet research criteria for
APSS. SIPS/SOPS psychometric instruments and DSM-5 criteria
were both used to diagnose DSM-5-APS in a precise way.
Clinical and Functional Assessments
Additional rating scales were administered to both adolescents
and their caregivers, including the Clinical Global Impression–
Severity scale (CGI-S; range = 1–7) to assess the overall severity
of illness (54) and Global Assessment of Functioning (GAF) scale
(55) to assess global functioning. Social and role functioning were
assessed as well, using the Global Functioning: Social (GF: Social)
and the Global Functioning: Role (GF: Role) (56, 57) scales.
Insight was assessed using the Scale to Assess Unawareness of
Mental Disorder (SUMD) (58), using three general awareness
items: mental disorder, social consequences of mental disorder,
and achieved effect of medication. Suicidality was assessed as the
% of individuals who reported suicidal ideation lifetime and those
with a history of at least one suicide attempt prior to admission.
Data Analysis
We used descriptive statistics to characterize the study
population, including diagnosis according to DSM-5 criteria,
demographic variables, clinical characteristics and treatment
characteristics. Between-group comparisons of categorical
variables were performed using χ2-test or Fisher’s exact
test, whenever at least one cell contained ≤5 patients. For
comparisons of continuous variables, we used t-test. The
following effect sizes were calculated: (a) Cramer’s V for χ2 (59),
which was interpreted as follows: 0.1=small; 0.3=moderate;
0.5=large effect size; and (b) Cohen’s d (60) for t-test, which
was interpreted as follows: 0.2=small; 0.5=moderate; 0.8=large
effect size, using effect size calculator for t-test (61). We
correlated attenuated positive, negative, general and disorganized
symptoms with the level of functioning and severity of illness
using Pearson’s correlation.We finally conducted amultivariable,
backward logistic regression analysis, entering into the model
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FIGURE 2 | Flowchart outlining selection of study population. SIPS, Structured Interview for Psychosis-Risk Syndromes.
variables that were significantly different (p < 0.05) between
APS vs. non-APS groups in univariate analyses with data in
>67% of subjects. For DSM-5 diagnoses, we entered into the
multivariable model broad diagnostic categories (e.g., anxiety
disorders), instead of single diagnoses (e.g., panic disorder),
that were significantly different between the APS and non-APS
group, in order to maximize power for the analyses. For the SIPS
psychopathology symptoms, we included only individual items
and not subscale sum scores to identify potentially clinically
relevant symptoms that can guide clinical identification of APS
status. The percent variance explained by the significant variables
retained in the final multivariable logistic regression model was
expressed as r2. Significance level was set at alpha=0.05, and all
tests were two-tailed. Statistical analyses were performed with
SPSS 21 for Windows software (IBM) (62).
RESULTS
Demographic, Comorbidity and Treatment
Characteristics
Altogether, 403 help-seeking adolescents and their
guardians/legal representatives were consented into AMDPS.
Of those, 79 (16.9%) were excluded from this study due to
incomplete information on the SIPS, and of the remaining
324 patients, 76 (23.5%) had a psychotic disorder and were
therefore also excluded. Finally, 248 hospitalized adolescents
with non-psychotic psychiatric disorders were included in this
study. Of those, 65 (26.2%) fulfilled DSM-5-APS criteria and 183
(83.8%) did not fulfill APS criteria (Figure 2). Agreement was
100% between DSM-5 clinical criteria and the SIPS.
Table 1 shows the demographic, illness and baseline
treatment characteristics of the sample at the time of the
interview. The average age of participants was 15.4 years
(SD=1.5). Most participants were female (69.4%) and white
(54.6%). There were no significant differences between
the two groups in any of the demographic characteristics
(Table 1).
APS individuals had a higher number of comorbid disorders
(3.5 vs. 2.4, p < 0.001; Cohen’s d = 0.77) compared
to non-APS individuals. The most frequent in the total
sample (APS plus non-APS) were depressive disorders (77.0%),
particularly major depressive disorder (55.2%), followed by
anxiety disorders (42.7%), and disruptive behavior disorders
(39.1%). The following disorders were significantly more
common in individuals with APS vs. non-APS: disruptive
behavior disorders (p = 0.011; Cramer’s V = 0.16), including
oppositional defiant disorder (p = 0.03; Cramer’s V = 0.14),
and conduct disorder (p = 0.049; Cramer’s V = 0.12); bipolar
disorders (p = 0.002, Cramer’s V = 0.20), including other
specified bipolar and related disorders (p = 0.005; Cramer’s
V = 0.18)—also known as bipolar disorder NOS as defined
by the COBY study criteria (63)–; personality disorder traits
(p < 0.001; Cramer’s V = 0.26), including borderline personality
disorder traits (p = 0.002; Cramer’s V = 0.20) and other
personality disorder traits (p < 0.001; Cramer’s V = 0.27);
anxiety disorders (p = 0.016; Cramer’s V = 0.15), including
panic disorder (p = 0.031; Cramer’s V = 0.14), generalized
anxiety disorder (p = 0.011; Cramer’s V = 0.16) and specific
phobia (p = 0.005; Cramer’s V = 0.18); and eating disorders
(p = 0.012; Cramer’s V = 0.16). The two groups did
not differ in comorbid depressive disorders, substance use
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TABLE 1 | Demographic, comorbidity and treatment characteristics.
Total
(n = 248)
APS
(n = 65)
Non-APS
(n = 183)
P-value Effect size
Demographic characteristics
Sex, male, n (%) 76 (30.6) 16 (24.6) 60 (32.8) 0.22 0.078
Age (years) mean ± SD 15.4 ± 1.5 15.5 ± 1.3 15.4 ± 1.5 0.63 0.070
Race/ethnicity, n, (%)a 0.60 0.11
White 124 (54.6) 32 (55.2) 92 (54.4)
Black or African American 41 (18.1) 13 (22.4) 28 (16.6)
Other 31 (13.7) 8 (13.8) 23 (13.6)
Asian or Pacific Islander 28 (12.3) 5 (8.6) 23 (13.6)
Indian American 3 (1.3) 0 (0.0) 3 (1.8)
Estimated IQ, mean ± SD 108.4 ± 18.9 107.2 ± 17.8 108.8 ± 19.3 0.56 0.088
Lifetime consensus diagnoses, n (%)
Number of psychiatric diagnoses 2.6 ± 1.5 3.5 ± 1.5 2.4 ± 1.4 <0.001 0.77
Depressive disorders 191 (77.0) 52 (80.0) 139 (76.0) 0.51 0.042
Major depressive disorder 137 (55.2) 42 (64.6) 95 (51.9) 0.077 0.11
Other specified depressive disorder 53 (21.4) 10 (15.4) 43 (23.5) 0.170 0.087
Persistent depressive disorder 18 (7.3) 5 (7.7) 13 (7.1) 0.87 0.010
Disruptive, impulse-control and conduct disorders 97 (39.1) 34 (52.3) 63 (34.4) 0.011 0.16
Attention-deficit/hyperactivity disorder 58 (23.4) 13 (20.0) 45 (24.6) 0.45 0.048
Oppositional defiant disorder 40 (16.1) 16 (24.6) 24 (13.1) 0.03 0.14
Conduct disorder 26 (10.5) 11 (16.9) 15 (8.2) 0.049 0.12
Disruptive behavior disorder not otherwise specified 11 (4.4) 4 (6.2) 7 (3.8) 0.43 0.050
Bipolar disorders 57 (23.0) 24 (36.9) 33 (18.0) 0.002 0.20
Other specified bipolar and related disorder 41 (16.5) 18 (27.7) 23 (12.6) 0.005 0.18
Bipolar I disorder 12 (4.8) 6 (9.2) 6 (3.3) 0.055 0.12
Bipolar II disorder 8 (3.2) 3 (4.6) 5 (2.7) 0.46 0.047
Personality disorder traits 48 (19.4) 24 (36.9) 24 (13.1) <0.001 0.26
Borderline personality disorder traits 42 (16.9) 19 (29.2) 23 (12.6) 0.002 0.20
Other personality disorder traits 13 (5.2) 10 (15.4) 3 (1.6) <0.001 0.27
Substance use disorders 39 (15.7) 13 (20.0) 26 (14.2) 0.27 0.070
Cannabis use disorder 31 (12.5) 9 (13.8) 22 (12.0) 0.70 0.024
Alcohol use disorder 14 (5.6) 6 (9.2) 8 (4.4) 0.14 0.093
Others 6 (2.4) 2 (3.1) 4 (2.2) 0.67 0.026
Trauma- and stressor-related disorders 38 (15.3) 8 (12.3) 30 (16.4) 0.43 0.050
Posttraumatic stress disorder 20 (8.1) 7 (10.8) 13 (7.1) 0.35 0.059
Adjustment disorder 19 (7.7) 2 (3.1) 17 (9.3) 0.11 0.10
Anxiety disorders 106 (42.7) 36 (55.4) 70 (38.3) 0.016 0.15
Panic disorder 63 (25.4) 23 (35.4) 40 (21.9) 0.031 0.14
Generalized anxiety disorder 37 (14.9) 16 (24.6) 21 (11.5) 0.011 0.16
Social phobia 24 (9.7) 10 (15.4) 14 (7.7) 0.07 0.11
Others 20 (8.1) 5 (7.7) 15 (8.2) 0.90 0.008
Obsessive-compulsive disorder 13 (5.2) 6 (9.2) 7 (3.8) 0.093 0.11
Specific phobia 9 (3.6) 6 (9.2) 3 (1.6) 0.005 0.18
Other diagnostic categories
Eating disorders 20 (8.1) 10 (15.4) 10 (5.5) 0.012 0.16
Enuresis (not due to a general medical condition) 9 (3.6) 3 (4.6) 6 (3.3) 0.62 0.031
Treatment characteristics at time of the interview n (%)b
Antipsychoticsc 118 (53.6) 37 (66.1) 81 (49.4) 0.031 0.15
Antidepressantsd 112 (50.9) 24 (42.9) 88 (53.7) 0.16 0.094
Mood stabilizerse 55 (25.0) 14 (25.0) 41 (25.0) 1.0 0.000
(Continued)
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TABLE 1 | Continued
Total
(n = 248)
APS
(n = 65)
Non-APS
(n = 183)
P-value Effect size
Lithium 41 (18.6) 9 (16.1) 32 (19.5) 0.57 0.038
Anxiolyticsf 23 (10.5) 7 (12.5) 16 (9.8) 0.56 0.039
Othersh 21 (9.5) 7 (12.5) 14 (8.5) 0.38 0.059
Antiepileptic drugs 18 (8.2) 6 (10.7) 12 (7.3) 0.42 0.054
ADHD medicationg 4 (1.8) 0 (0.0) 4 (2.4) 0.24 0.080
Two or more drugs 91 (41.4) 22 (39.3) 69 (42.1) 0.71 0.025
Three or more drugs 25 (11.4) 7 (12.5) 18 (11.0) 0.76 0.021
ADHD, Attention Deficit Hyperactivity Disorder; APS, Attenuated Psychosis Syndrome.
a Information available for 227 individuals.
b Information available for 220 individuals.
cAntipsychotics: aripiprazole, molindone, quetiapine, risperidone, lurasidone, ziprasidone, olanzapine, haloperidol, chlorpromazine, clozapine.
dAntidepressants: amitriptyline, nortriptyline, bupropion, citalopram, escitalopram, duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine, mirtazapine.
eMood stabilizers: lamotrigine, lithium, valproic acid.
fAnxiolytics/tranquilizers: clonazepam, lorazepam, hydroxyzine, buspirone.
gAnti-ADHD medications: atomoxetine, lisdexamphetamine, methylphenidate, modafinil, clonidine, guanfacine.
hOthers: zolpidem, melatonin, propranolol, diphenhydramine, amlodipine.
Bold values indicate p < 0.05 for between-groups analysis.
disorders, trauma and stressor-related disorders or enuresis
(all p > 0.05).
Overall, the most used psychotropic medications at the time
of the interview were antipsychotics (53.6%; p= 0.031), followed
by antidepressants (50.9%; p = 0.16), and mood stabilizers
(25.0%; p = 1.0). Antipsychotics, which were more common
in the APS group (p = 0.031; Cramer’s V = 0.15), were the
only medication class that was significantly different between the
groups. The use of multiple medications (use of two or more
drugs or use of three or more drugs) was equally frequent in both
groups (p= 0.71 to 0.76).
Severity of Symptoms and Symptom
Domains
Total attenuated positive (p < 0.001; Cohen’s d = 1.5), negative
(p < 0.001; Cohen’s d = 0.55), disorganized (p < 0.001;
Cohen’s d = 0.51), and general (p < 0.001; Cohen’s d = 0.84)
symptom scores were significantly higher in APS individuals
vs. non-APS hospitalized adolescents. All group-defining
SIPS attenuated positive symptoms (unusual thought content,
suspiciousness, grandiosity, perceptual abnormalities and
disorganized communication) were significantly more severe in
the APS group (Cohen’s d = 0.39 to 1.3), with the largest effect
size for perceptual abnormalities (Cohen’s d = 1.3) (Table 2).
Additionally, the following symptoms were more severe in the
APS vs. non-APS group: social anhedonia (p < 0.001; Cohen’s
d = 0.57), avolition (p = 0.002; Cohen’s d = 0.51), experiences
of emotions and self (p < 0.001; Cohen’s d = 0.54), bizarre
thinking (p < 0.001; Cohen’s d = 0.60), trouble with focus and
attention (p = 0.001; Cohen’s d = 0.53), sleep disturbances
(p = 0.002; Cohen’s d = 0.38), dysphoric mood (p = 0.004;
Cohen’s d = 0.34) and impaired stress tolerance (p < 0.001;
Cohen’s d= 0.63).
Illness Severity, Functional Level, Illness
Insight and Suicidality
Overall illness severity (CGI-S) was higher in the APS group
(p<0.001) and the effect size was large (Cohen’s d = 1.0). The
mean current GAF score was 23.0 ± 11.9 in the APS group
and 28.1 ± 17.9 in the non-APS group (p = 0.012; Cohen’s
d = 0.31). Scores for the highest functioning in the past year
(p = 0.002; Cohen’s d = 0.52) and lowest functioning in the past
year (p = 0.002; Cohen’s d = 0.38) were lower in the APS group
as well (i.e., poorer functioning in the APS group). Unlike current
role functioning, which did not differ significantly between the
groups (p = 0.35), current social functioning was better in the
non-APS group (p= 0.003; d= 0.66). Both groups did not differ
regarding awareness of mental disorder or social consequences,
suicidal ideation or suicidal attempts (all p > 0.05) (Table 3).
Correlation Between Symptom Domains
and Functioning (GAF)–Severity of Illness
(CGI-S)
Total negative symptoms were significantly correlated with lower
current functioning (Pearson ρ=−0.17; p= 0.031), lower lowest
functioning in the past year (Pearson ρ = −0.20; p = 0.014)
and lower highest functioning reached in the past year (Pearson
ρ = −0.19; p = 0.022). Functioning was not significantly
correlated with attenuated positive symptoms, disorganized
symptoms or general symptoms. The severity of illness was
associated with more severe SIPS positive, negative, disorganized
and general symptoms (Pearson ρ = 0.22 to 0.46; p = 0.04 to
p < 0.001) (Table 4).
Multivariable Logistic Regression Analysis
Independent correlates of APS in the final model were perceptual
abnormalities (OR = 2.0; 95% CI = 1.6–2.5, p < 0.001), number
of psychiatric diagnoses (OR= 1.5; 95% CI= 1.2–2.0, p= 0.002),
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TABLE 2 | Severity of structured interview of prodromal syndromes (SIPS) assessed symptoms and symptom domains.
Total
(n = 248)
APS
(n = 65)
Non-APS
(n = 183)
P-value Effect size
Structured interview of prodromal syndromes mean± SD
Positive symptoms
Total positive symptom score 3.2 ± 4.1 7.4 ± 4.6 1.9 ± 3.3 <0.001 1.5
Highest positive symptom score 1.8 ± 1.8 3.5 ± 1.3 1.2 ± 1.6 <0.001 1.5
P1 unusual thought content 0.73 ± 1.4 1.6 ± 1.6 0.41 ± 1.1 <0.001 0.95
P2 suspiciousness 0.84 ± 1.3 1.8 ± 1.6 0.48 ± 0.93 <0.001 1.2
P3 grandiosity 0.54 ± 1.2 0.89 ± 1.5 0.41 ± 1.1 0.024 0.39
P4 perceptual abnormalities/hallucinations 0.99 ± 1.7 2.3 ± 1.9 0.47 ± 1.2 <0.001 1.3
P5 disorganized communication 0.29 ± 0.86 0.63 ± 1.1 0.16 ± 0.68 <0.001 0.58
Negative symptoms
Total negative symptom score 8.0 ± 6.22 10.4 ± 6.7 7.1 ± 5.8 <0.001 0.55
Highest negative symptom score 3.4 ± 1.83 3.8 ± 1.6 3.2 ± 1.9 0.012 0.33
N1 social anhedonia 1.5± 1.79 2.2 ± 1.9 1.2 ± 1.7 <0.001 0.57
N2 avolition 2.1 ± 2.0 2.9 ± 1.7 1.9 ± 2.0 0.002 0.51
N3 expression of emotions 0.88 ± 1.5 1.2 ± 1.6 0.75 ± 1.4 0.061 0.31
N4 experience of emotions and self 0.87 ± 1.7 1.6 ± 2.3 0.65 ± 1.4 <0.001 0.54
N5 ideational richness 0.20 ± 0.65 0.18 ± 0.18 0.21 ± 0.75 0.88 0.050
N6 occupational functioning 2.4 ± 2.1 2.5 ± 2.4 2.3 ± 2.0 0.31 0.11
Disorganized symptoms
Total disorganized symptom score 3.1 ± 3.2 4.3 ± 3.7 2.7 ± 2.9 <0.001 0.51
Highest disorganized symptom score 2.2 ± 1.9 2.9 ± 1.7 2.03 ± 1.9 0.003 0.47
D1 odd behavior or appearance 0.16 ± 0.94 0.14 ± 1.4 0.17 ± 0.71 0.297 −0.03
D2 bizarre thinking 0.18 ± 0.7 0.48 ± 1.1 0.08 ± 0.4 <0.001 0.60
D3 trouble with focus and attention 1.9 ± 1.8 2.6 ± 1.7 1.66 ± 1.81 0.001 0.53
D4 impairment in personal hygiene 0.76 ± 1.7 0.86 ± 2.1 0.73 ± 1.54 0.45 0.08
General symptoms
Total general symptom score 8.4 ± 4.5 11.0 ± 3.5 7.5 ± 4.4 <0.001 0.84
Highest general symptom score 4.3 ± 1.7 5.0 ± 1.1 4.1 ± 1.8 <0.001 0.55
G1 sleep disturbance 2.3 ± 1.9 2.8 ± 2.0 2.1 ± 1.8 0.002 0.38
G2 dysphoric mood 4.0 ± 2.1 4.5 ± 2.3 3.8 ± 2.0 0.004 0.34
G3 motor disturbance 0.14 ± 0.80 0.17 ± 1.4 0.13 ± 0.52 0.73 0.05
G4 impaired stress tolerance 1.9 ± 2.1 2.9 ± 2.3 1.6 ± 1.9 <0.001 0.63
Bold values indicate p < 0.05 for between-groups analysis.
and impaired stress tolerance (OR = 1.4; 95%CI = 1.1–1.7,
p = 0.002). The model including these three variables explained
31.5% of the variance (r2 = 0.315, p < 0.001) (Table 5).
DISCUSSION
To our knowledge, this study is one of the very few and the
largest to date to characterize and describe sociodemographic,
illness and intervention characteristics in adolescents with APS
vs. non-APS. Additionally, this study focused on help-seeking
adolescents who had been admitted into an inpatient unit.
According to our results, 26.2% of the adolescents without a
psychotic disorder diagnosis fulfilled APS criteria, a somewhat
lower prevalence compared to a previous study including mostly
adolescent outpatients (33%) (64, 65), but still a clinically
significant and higher prevalence than the one found in non-
help-seeking adolescents with disruptive behaviors (13%) (33).
In the general population, a 7.2% meta-analytical prevalence of
psychotic experiences was estimated in children and adults (66).
In the Philadelphia Neurodevelopmental Cohort study, 15.5%
of the 8–21 year old individuals reported significant psychotic
symptoms and another 9.8% reported milder symptoms (67).
APS individuals had a higher number and distribution
of comorbid conditions than non-APS individuals (Cohen’s
d = 0.77), particularly consisting of depressive disorders (5),
anxiety disorders (5), and disruptive behavior disorders (68).
This finding is clinically relevant because APS status has been
associated with hospital treatment for mood and conduct
disorders (33). Personality disorder traits, bipolar disorders,
disruptive behavior disorders, eating disorders and anxiety
disorders, were more frequent in the APS group than the
non-APS group, although effect sizes were small. This result
supports evidence of the association between APS (21, 22) as
well as CHR-P (9, 69) with other comorbid mental disorders.
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TABLE 3 | Illness severity, functional level, illness insight and suicidality.
Total
(n = 248)
APS
(n = 65)
Non-APS
(n = 183)
P-value Effect size
Characteristics
Illness severity: clinical global impressions-severity scale (CGI-S) mean ± SDa
Overall severity of illness 4.2 ± 1.03 4.8 ± 0.94 3.9 ± 0.9 <0.001 1.0
Functional level: global assessment of functioning-scale (GAF) mean ± SDb
Current GAF 26.8 ± 16.7 23.0 ± 11.9 28.1 ± 17.9 0.012 0.31
Highest GAF of past year 57.7 ± 14.7 52.2 ± 16.6 59.7 ± 13.5 0.002 0.52
Lowest GAF of past year 23.1 ± 15.0 18.9 ± 10.2 24.5 ± 16.0 0.002 0.38
Global functioning: role scale mean ± SDc
Current role functioning 5.9 ± 1.8 5.7 ± 1.7 6.1 ± 1.9 0.35 0.20
Global functioning: social scale mean ± SDc
Current social functioning 6.5 ± 1.7 5.8 ± 1.5 6.9 ± 1.7 0.003 0.66
Scale to assess unawareness of mental disorder mean ± SDd
Awareness of mental disorder 2.2 ± 1.7 2.2 ± 1.6 2.2 ± 1.7 0.98 0.006
Awareness of the effect of medication 2.1 ± 1.5 2.2 ± 1.5 2.0 ± 1.5 0.45 0.14
Awareness of the social consequences 1.9 ± 1.5 1.9 ± 1.4 1.9 ± 1.5 0.99 0.0
Suicidality, n (%)e
Suicidal ideation 131 (61.8) 38 (73.1) 93 (58.1) 0.29 0.067
Suicide attempts 21 (10.0) 8 (15.3) 13 (8.2) 0.19 0.082
aData available for 86 patients.
bData available for 225 patients.
cData available for 88 patients.
dData available for 168 patients.
eData available for 212 patients.
Bold values indicate p < 0.05 for between-groups analysis.
TABLE 4 | Correlation between Structured Interview of Prodromal Syndromes (SIPS) symptom domains and functioning as well as severity of illness.
Current GAF Lowest GAF past year Highest GAF past year Severity of illness CGI-S
Pearson’s Rho p-value Pearson’s Rho p-value Pearson’s Rho p-value Pearson’s Rho p-value
Total SIPS positive symptom score −0.034 0.66 −0.045 0.57 0.0005 0.95 0.46 <0.001
Total SIPS negative symptom score −0.17 0.031 −0.20 0.014 −0.19 0.022 0.39 <0.001
Total SIPS disorganized symptom score −0.04 0.58 −0.06 0.46 −0.043 0.61 0.22 0.04
Total SIPS general symptom score 0.095 0.21 0.082 0.3 0.017 0.36 0.45 <0.001
CGI-S, Clinical Global Impression–Severity scale; GAF, Global Assessment of Functioning; SIPS, Structured Interview for Psychosis-Risk Syndromes.
Bold values indicate p < 0.05 for between-groups analysis.
TABLE 5 | Results of the multivariable, backward elimination logistic regression analysis of variables distinguishing APS vs. non-APS at p < 0.05 in univariate analyses.
B SE Wald Sig OR 95.0% C.I.
Lower Upper
SIPS P4 perceptual abnormalities/hallucinations 0.69 0.11 38.9 <0.001 2.0 1.6 2.5
SIPS G4 impaired stress tolerance 0.31 0.10 9.8 0.002 1.4 1.1 1.7
Number of psychiatric diagnoses 0.42 0.14 9.5 0.002 1.5 1.2 2.0
(r2 = 0.315, p < 0.001).
Bold values indicate p < 0.05 for between-groups analysis.
Thus, comorbidity should not rule out APS, but, if anything,
increase the diagnostic suspicion. On the other hand, it is
also possible for APS status to be a byproduct of overlapping
disease processes and expressions of non-psychotic disorders,
lowering the true risk for developing a psychotic disorder in the
future (22, 28, 70).
Regarding psychopharmacological treatment, as previously
reported (22), a high percentage of our non-psychotic APS
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sample received atypical antipsychotics (66.1%), which was
also high in the non-psychotic non-APS individuals (49.4%).
This finding is worrying because no consistent meta-analytical
evidence supports the use of atypical antipsychotic drugs
in delaying or preventing transition to psychosis over other
interventions (71, 72). However, it is also true that rates
of antipsychotics were high in other diagnostic groups in
this sample, including bipolar-spectrum disorders (49), which
supports that atypical antipsychotic use is likely related to
the reason for admission to the psychiatric unit and not
only to efforts to treat attenuated psychotic symptoms or to
prevent full-blown psychosis. Nevertheless, the widespread use of
antipsychotics in adolescents for non-psychotic, predominantly
depressive disorders is concerning due to the established adverse
effects risks that atypical antipsychotics have in youth (73–77).
APS status was associated with a significantly higher severity
of attenuated psychotic symptoms according to the SIPS. Effect
sizes for these differences were moderate to large (Cohen’s
d = 0.51 to 1.5). Regarding individual items, differences were
found in 13/19 items. Effect sizes were large for unusual thought
content, suspiciousness and perceptual abnormalities (Cohen’s
d = 1.0 to 1.3), medium for disorganized communication, social
anhedonia, avolition, experience of emotions and self, bizarre
thinking, trouble with focus and attention and impaired stress
tolerance (Cohen’s d = 0.50 to 0.63), and small for grandiosity,
sleep disturbances and dysphoric mood (Cohen’s d = 0.34
to 0.39).
This greater severity in psychopathology also translated into
greater illness severity (Cohen’s d = 1.0) and poorer functioning
(Cohen’s d = 0.31 to 0.52), as found before (9, 22, 78,
79), including social functioning (Cohen’s d = 0.66), but not
role functioning. However, a previous study using the same
instruments found that both social and role functioning were
significantly more impaired in CHR-P individuals compared to
controls from as early as age 12, which was our lower age limit
(80). However, controls in that study were healthy, while in our
sample, we compared hospitalized adolescents with vs. without
APS who were likely admitted for symptoms related to other
psychiatric disorders, which can explain the difficulties in role
functioning as well as social and general functioning. The fact
that all adolescents (APS and non-APS) reached stringent US
criteria for inpatient care resulted in the low functioning scores
found in both groups. Nevertheless, our results support previous
evidence that APS status is associated with marked functional
impairment (21, 81, 82). This finding is particularly relevant
because functional impairment can be helpful to differentiate
youth meeting CHR-P from other help-seeking individuals (83).
Interestingly, while illness severity was associated with
overall psychopathology, including more severe SIPS total
positive, negative, disorganized and general symptoms (Pearson
ρ = −0.22 to −0.46), functioning (current, lowest and
highest) was only and weakly (Pearson ρ = −0.17 to
−0.20) correlated with total negative symptoms, but not
with attenuated positive, disorganized and general symptoms.
Negative symptoms have been associated with functioning (38–
40), not only in schizophrenia, but also in other psychotic
individuals, and non-psychotic depressed patients (84). This
association was found to be greater with negative than attenuated
positive symptoms (85), in line with our results. In contrast,
trauma has been found to be correlated with the severity of
attenuated positive symptoms but not with negative symptoms
in CHR-P individuals (86); yet, CHR-P individuals’ negative
symptomsmay impact the transition to psychosis evenmore than
attenuated positive symptoms (87), although this has not been
found consistently (53).
According to our results, perceptual abnormalities (OR=2.0),
number of psychiatric diagnoses (OR=1.5), and impaired stress
tolerance (OR=1.4) were independently associated with APS
status. Among perceptual abnormalities, auditory perceptual
abnormalities have been associated with a higher risk of
psychosis, while visual perceptual abnormalities have been
associated with a lower risk (88).While the number of psychiatric
diagnoses was independently associated with APS status in
our study, and while APS has previously been associated with
comorbid mental disorders, the impact of the different comorbid
conditions may vary (21, 22). The most common comorbid
conditions in our sample, anxiety and depressive diagnoses, have
been associated with impaired global functioning, as well as
higher suicidality or self-harm behaviors, but not with transition
to psychosis (5). Implications of the presence of other comorbid
conditions in APS and their relevance for true risk for conversion
to psychosis need further study, particularly in adolescents. Our
results further support previous evidence that impaired stress
tolerance is a core CHR-P feature, which is associated with
more severe psychopathology (89). The presence of impaired
stress tolerance has been also suggested to have therapeutic
implications in CHR-P (90).
We also found that APS was associated with functioning in
univariate analyses, but not in multivariable analyses, supporting
that lower functioning is related to other features, including
the presence and duration of attenuated positive symptoms
(21, 91) and impaired stress tolerance (89). A model including
disorganized communication, suspiciousness, verbal memory
deficits, and decline in social functioning was found to predict
conversion to psychosis (53). Due to having introduced the
Global Functioning scales later into the study, they were
only available in a subset of patients and could not be
entered into the backward elimination logistic regression model.
However, APS was associated with significantly lower levels of
social functioning. Clinicians should thus monitor functioning,
especially social functioning in adolescents with APS.
Finally, our results stress that in adolescent inpatients, DSM-
5 APS is associated with higher severity of overall illness, lower
functioning and impaired stress tolerance, requiring a higher
intensity of clinical care compared to non-APS adolescents
admitted into an inpatient unit. This result is supported by prior
findings showing that youth with APS have complex medical
histories and frequent comorbidities that require therapeutic
attention (22, 28, 70). Research about effective treatments for
DSM-5-APS has been limited (21), and evidence from studies
analyzing CHR-P individuals—from which knowledge could
arguably be applied to APS individuals—does not support one
treatment over another (72). At the moment, at least needs-based
interventions should be offered (9). Perceptual abnormalities
and impaired stress tolerance may be targets of needs-based
interventions in adolescents aiming to improve quality of life
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and aiming to reduce burden for them and their families. Still,
prospective studies are needed to inform and develop guidelines
regarding youth fulfilling APS criteria.
Strengths and Limitations
The current study has several strengths and limitations that
must be taken into consideration when interpreting its results.
First, some symptom assessments were based on retrospective
recall, which may be prone to recall bias. However, all SIPS
symptoms were rated for presence in the last month. Second,
the comparison group, including non-psychotic adolescents who
fulfilled criteria for inpatient care in the US health care system,
was otherwise heterogeneous and functionally impaired. The
results should thus be interpreted in the context of help-seeking
APS and non-APS samples in need of inpatient care. Third,
data were not available to determine to what degree adolescents
with APS sought help specifically for APS-related symptomology.
Fourth, we did not collect some potentially relevant information,
including the reason for the use of psychotropic medications or
dosage, which could have relevant implications. Similarly, verbal
memory deficits and other cognitivemeasures, which are relevant
according to previous research, were not included in the current
analysis. Fifth, we could not retrieve the data for the total number
of patients fulfilling our inclusion criteria within our study
timeframe outside of this study. Thus, we could not report the
participation rate. Sixth, we did not test for interrater reliability
of interviewers for all scales used in this study. However, using
the same training, certification and ongoing recalibration system
via mandatory presence and presentation of all rating scale scores
for all interviewers as part of the regular diagnostic consensus
conference (led by the study PI CUC) the interrater reliability
of the BPSS-FP indices ranged from intraclass-correlations of
0.93–0.98 (92). Seventh, since the Clinical Global Impressions of
Severity Scale and social and role function scales were introduced
later into the study, data were not available in a sufficiently large
number of patients to enter this variable into the multivariable
regression analysis; Eighth, the final model obtained from the
multivariable regression analysis was not validated, which may
have led to overfitting, thus requiring replication and limiting its
generalizability and consequently its implementation in clinical
practice. Finally, the cross-sectional design precludes any analysis
of the predictive value of APS.
Nevertheless, despite these limitations, the study has
several strengths. First, this is the largest study to date to
comprehensively describe and characterize DSM-5-APS
in adolescents. Second, we used structured and validated
assessments that were carried out independently and face-to-face
for both adolescents and their parents or caregivers to obtain as
precise information as possible. These assessments were led by
experienced and internally certifiedMaster orMD level clinicians
and psychologists. Third, we focused on individuals with a wide
variety of psychopathology and treatment characteristics, both in
the DSM-5-APS group and in the non-APS comparison group,
increasing clinical value vs. comparisons with healthy control
subjects. Finally, focusing on APS individuals allowed us to
obtain results from a more homogeneous high-risk sample.
CONCLUSIONS
Approximately one in four adolescents hospitalized with non-
psychotic disorders meet DSM-5-APS criteria. These help-
seeking adolescents have more comorbid psychiatric disorders as
well as more severe symptoms, functional impairment and global
severity of illness. Thus, they warrant high intensity clinical care.
To what degree APS in adolescents with existing and emerging
non-psychotic mental disorders is predictive of future transition
to a psychotic disorder and what the predictors are for such
transition requires further prospective study.
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